APLS
NASDAQ · Biotechnology
Apellis Pharmaceuticals Inc
$41.03
-0.03 (-0.07%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+0.02%
1Y
+113.03%
YTD
+58.66%
Open$41.05
Previous Close$41.06
Day High$41.07
Day Low$41.03
52W High$41.14
52W Low$16.83
Volume—
Avg Volume11.48M
Market Cap5.25B
P/E Ratio39.41
EPS$1.00
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$33.20
Above
SMA 200
$26.08
Above
RSI (14)
58.7
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Hold
27 analysts
Price Target
-45.1% upside
Current
$41.03
$41.03
Target
$22.54
$22.54
$12.93
$22.54 avg
$29.12
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.02B | 3.03B | 2.81B |
| Net Income | 22.72M | 93.04M | 81.85M |
| Profit Margin | 2.2% | 3.1% | 2.9% |
| EBITDA | 57.83M | 115.17M | 115.66M |
| Free Cash Flow | — | 42.87M | 48.47M |
| Rev Growth | +137.0% | +21.3% | +20.6% |
| Debt/Equity | 1.23 | 0.57 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |